About Alercell
Alercell makes tests that detect leukemia and lung cancer earlier. Its LENA platform uses artificial intelligence to study chemical marks on DNA, known as methylation. LENA Q51 is a research-use leukemia test, while LENA PAN-MPN expands the leukemia testing platform. LENA S1 looks for methylated genes linked to lung cancer. The broader platform includes four products for leukemia.
Based in Bozeman, Montana, Alercell is led by founder, chief executive officer and chief science officer Frederic Scheer. It announced a Milan subsidiary in October 2020 and opened Alercell UK with a London office in February 2023. In 2026, it added three advisory board members. Jim Stipcich became vice president of business development and strategic partnerships that October.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 12, 2026 | Oct 19, 2026 | $35,000of $1.5M target | 3 | $11,667 | EquityRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Alercell
Alercell is pursuing earlier cancer detection through AI-assisted molecular diagnostics. Its current products cover research-use leukemia testing and early lung cancer detection. The LENA platform groups these tests into a broader monitoring system.
The problem it targets
Alercell's premise is that pre-leukemic molecular changes can appear well before a diagnosis. Its approach tracks chemical marks on DNA before symptoms. The platform detects leukemia up to 41 months before symptoms.
What the product does
The LENA platform combines AI analysis with molecular diagnostics. It groups four leukemia tests under one platform. Q51 is labeled for research use, PAN-MPN expands leukemia testing and S1 examines methylated genes for early lung cancer detection. Advisers also help move LENA toward clinical use and guide research on LENA-Rx.
Progress so far
Alercell introduced research-use Q51 for commercial sale in January 2023 and launched its molecular leukemia platform that April. It received a 2023 GHP award for oncology testing in Montana, then added PAN-MPN and S1 in 2024. The company pitched at Startup Grind and Founders of the Mountain West in 2025. By March 2026, its validation work covered more than 199,000 patient records. Partnership work for a planned pilot was underway by October 2026.
Who backs it
Alercell is seeking a Series A. The financing is open to qualified investors. It views federal grant funding as independent validation of its science.
We wrote this summary from public statements by Alercell and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Alercell's Form D filed Oct 19, 2026.